Introduction {#s1}
============

The number and pattern of hair follicles (HFs) are specified before birth in humans. In the mouse this is true for most body areas such as back skin ([@bib2]; [@bib25]; [@bib26]). HF morphogenesis requires Hedgehog (Hh) and Wnt/β-catenin signaling and becomes first morphologically visible at embryonic day 14.5 (E14.5) in mice ([@bib9]; [@bib14]; [@bib22]; [@bib35]). At this stage, the embryonic hair germ has formed, consisting of an epithelial placode and a dermal condensate, whose epithelial-mesenchymal crosstalk is essential for further HF development ([@bib15]; [@bib32]).

De novo HF formation in adult skin has been observed in combination with wounding in rabbits, mice, and humans ([@bib6]; [@bib16]; [@bib19]; [@bib21]), and in unwounded skin as a response to forced epithelial Wnt/β-catenin signaling in mice ([@bib14]; [@bib22]). Two decades after the initial discovery that Wnt/β-catenin-pathway activation results in ectopic HFs ([@bib14]), it is still the only known approach to induce de novo HFs in adult unwounded skin. Accordingly, it remains a major clinical challenge to generate replacement skin with hair, urging the search for new ways to achieve HF formation in adult skin.

In Sonic hedgehog knock out (Shh-/-) mice, HF morphogenesis does not progress beyond the hair germ stage ([@bib35]). Notably, compared to wild type skin, Shh-/- hair germs have normal levels of Wnt/β-catenin signaling but reduced Hh-target activation in both the placode and the dermal condensate ([@bib9]; [@bib35]). Despite the well-known importance of Hh signaling for HF morphogenesis during embryonic skin development ([@bib5]; [@bib24]; [@bib35]) and in wound-induced HF formation ([@bib21]), little is known about its potential for de novo HF induction in adult unwounded skin.

Interestingly, already decades ago it has been observed that basal cell carcinoma (BCC) morphologically mimics HF development until the hair germ stage. BCC develops upon supra-physiological Hh-pathway activation in epithelial cells, with the most prevalent mutations in the inhibitory Hh-receptor gene *Ptch1*. Like HF formation, Hh-driven BCC is characterized by active Wnt/b-catenin signaling ([@bib38]), and early epithelial BCC buds express typical HF-lineage markers even if they don\'t originate from HFs ([@bib18]; [@bib38]; [@bib40]). Morphologically and molecularly, these early BCC buds are thus very similar to embryonic hair germs with one major difference: BCC buds lack a dermal condensate which serves as a focal point for dermal Hh signaling and is required for HF morphogenesis ([@bib38]).

Based on these observations, we hypothesized that HF development past the hair germ stage in BCC requires Hh signaling at increased levels in both epithelial and stromal cells. To address this hypothesis, we used mouse models to induce supra-physiological Hh signaling via *Ptch1* deletion in the epithelium and stroma, which indeed led to the induction of new HFs in adult unwounded skin.

Results {#s2}
=======

Activated Hh signaling in *Gli1*-expressing cells induced HF-like structures in touch domes {#s2-1}
-------------------------------------------------------------------------------------------

To test whether activation of epithelial and stromal Hedgehog signaling would result in HF formation, we focused on the touch domes (TDs), which are touch-receptive structures located within the interfollicular epidermis (IFE) ([Figure 1A,B](#fig1){ref-type="fig"}). We reasoned that in adult unwounded skin, TDs were the most likely places to achieve experimentally induced de novo HFs because TDs are hotspots for BCC formation ([@bib27]), which resembles HF development ([@bib38]).

![Formation of hair follicle (HF)-like structures in touch domes (TDs) of the Gli1 mouse model.\
(**A--B**) Illustrative cartoon of HF and TD structures in wild type skin. Physiological Hh signaling is present in both TD epithelium and TD stroma. The presence of K8+ Merkel cells is characteristic for TDs. (**C**) Schematic representation of the experimental timeline and the Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ and Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mouse models. (**D--E**) *Lgr6*^EGFP^ and *Gli1*^LacZ^ expression in dorsal telogen skin. Filled arrowhead: indicates *Lgr6*-expression in the HF infundibulum. Empty arrowheads: indicate lack of *Lgr6*- or *Gli1*-expression in HF infundibula (n = 3 mice per genotype). (**F--I**) Mice were treated with tamoxifen (TAM) at 8 weeks of age and dorsal skin was analyzed 5 weeks post TAM. For each genotype ≥3 mice and numerous TDs were analyzed ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). (**F**) Illustrative cartoon and experimental Tomato-tracing of *Lgr6*-expressing cells. TDs of Lgr6^creERT2^;R26^Tom^;Ptch1^fl/wt^ control skin were phenotypically normal. (**G**) Illustrative cartoon and experimental Tomato-tracing of *Gli1*-expressing cells. TDs of Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ control skin were phenotypically normal. (**H**) Tomato-traced TD of Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ skin displaying basal cell carcinoma (BCC)-like tumor growth. (**I**) Tomato-traced TD of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ skin with BCC-like tumor growth and several de novo HFs. Asterisks: mark a non-traced infundibulum in the pre-existing Guard HF adjacent to the TD. Inset: different z-levels better depicting specific de novo HF structures. A video containing all z-levels is provided ([Figure 1---video 1](#fig1video1){ref-type="video"}). Arrows: de novo HFs with continuous tracing into the IFE. Yellow arrow: anagen bulb of a de novo HF. Arrowheads: hair shaft (HS) or pigment (P). (**J**) Quantification of de novo HFs in the TDs of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ and Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice (9 weeks post TAM; n = 3 mice for each genotype). Asterisk: the Lgr6 mouse model cannot inform on de novo HFs trough lineage tracing; based on morphology we observed in two TDs a single potentially new hair shaft, respectively. TD: touch dome. HS: hair shaft. P: pigment. TAM: tamoxifen. BF: bright field. Scale bars: 50 μm (**D--I**).](elife-46756-fig1){#fig1}

We analyzed and compared the TDs of two mouse models with induced supra-physiological Hh-pathway levels in epithelial cells (Lgr6 mouse model), or combined epithelial and stromal cells of the TD (Gli1 mouse model). Specifically, we used *Lgr6-EGFP-IRES-Cre^ERT2^;R26^tdTomato^;Ptch1^fl/fl^* mice (hereafter: Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^) and *Gli1-Cre^ERT2^;R26^tdTomato^;Ptch1^fl/fl^* mice (hereafter: Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^). TD areas were identified by the presence of K8+ Merkel cells, and their palisading epithelial cell morphology. Tamoxifen was administered at 8 weeks of age, resulting in the constitutive activation of Hh signaling via homozygous inactivation of *Ptch1* and simultaneous Tomato-tracing of *Lgr6-* or *Gli1*-expressing cells ([Figure 1C](#fig1){ref-type="fig"}). First, we confirmed that *Lgr6* expression, and consequently Tomato-tracing, were in the TD restricted to epithelial cells ([Figure 1D,F](#fig1){ref-type="fig"}), and *Gli1* expression and Tomato-tracing were present in both epithelial and stromal TD cells ([Figure 1E,G](#fig1){ref-type="fig"}). Next, we analyzed the phenotypes of both Lgr6 and Gli1 mouse models 5 weeks post tamoxifen, a sufficiently long time to allow possible de novo HFs to form ([@bib28]). Homozygous *Ptch1* inactivation in *Lgr6*-expressing cells resulted as expected in BCC-like lesions in HFs, IFE and TDs ([Figure 1H](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [@bib27]). Strikingly, however, homozygous *Ptch1* inactivation in *Gli1*-expressing cells resulted in addition to BCC-like lesions in HFs and TDs, in the formation of structures in TDs that resembled de novo HFs ([Figure 1I](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). These structures had the appearance of typical concentric anagen HF layers and a pigmented hair bulb or mature hair shaft ([Figure 1I](#fig1){ref-type="fig"}, [Figure 1---video 1](#fig1video1){ref-type="video"}). Importantly, by 9 weeks post tamoxifen, these HF-like structures occurred in every single Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ TD examined (27/27) but extremely rarely in TDs of Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice (2/25; please also see Discussion) ([Figure 1J](#fig1){ref-type="fig"}). No such HF-like structures were observed in TDs of wild type mice (with physiological Hh signaling in epithelial and stromal cells), upon heterozygous *Ptch1* inactivation (Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ and Lgr6^creERT2^;R26^Tom^;Ptch1^fl/wt^) ([Figure 1F,G](#fig1){ref-type="fig"}), or in non-tamoxifen controls (Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ and Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Therefore, induction of supra-physiological Hh signaling in epithelial and stromal cells (Gli1 model) but not epithelial cells alone (Lgr6 model) was sufficient to induce HF-like structures in TDs of adult mouse skin.

Characterization of de novo HFs in touch domes {#s2-2}
----------------------------------------------

Next we investigated whether the observed structures were functional HFs, and indeed de novo induced. Thus, we stained the skin of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice for Keratin 71 (K71) and Keratin 6 (K6) ([Figure 2A](#fig2){ref-type="fig"}), which mark specific layers of the anagen HF ([@bib39]). These Keratin-staining patterns were very similar to those of hair-cycle stage-matched wild type anagen HFs ([Figure 2B](#fig2){ref-type="fig"}). Also, the presence, and specific pattern of hair pigment in these structures were typical for anagen HFs, in the shown picture matching the anagen III hair-cycle stage ([Figure 2A,B](#fig2){ref-type="fig"}), further supporting that the observed structures are indeed HFs and actively growing. At 5 weeks post tamoxifen all de novo HFs were in different stages of anagen ([Figures 1I](#fig1){ref-type="fig"} and [2A](#fig2){ref-type="fig"}) and by 9 weeks post tamoxifen the majority of de novo HFs were in telogen ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). This demonstrates that de novo HFs enter the hair cycle after their first anagen ([@bib26]).

![Characterization of de novo hair follicles (HFs) in Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl ^touch domes (TDs).\
(**A**) Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice were treated with tamoxifen (TAM) at 8 weeks and dorsal skin was analyzed 5 weeks post TAM treatment (n = 3 mice). The TD area shows a de novo anagen HF (turquois frame). Additionally, traced pre-existing (old) telogen HFs with basal cell carcinoma (BCC)-like growth are present. Inset (white frame): anagen hair bulb of de novo HF showing K71-positive Henle's layer, K6-positive companion layer, hair pigment and continuous Tomato-tracing from the hair bulb into the TD. (**B**) Immunofluorescent co-staining of K71 (Henle's layer) and K6 (companion layer) in a wild type HF of a similar hair cycle stage (Anagen IIIa, P27) (n = 2 mice). (**C**) Quantification of hair size in Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ and Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ mice that were treated with TAM at 8 weeks and dorsal skin was analyzed 9 weeks post TAM treatment. Right panel: De novo telogen HFs with a thin hair shaft formed in the TDs of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ skin (white arrow). For the quantification, we analyzed hair shafts of de novo HFs from Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice (blue bracket), old/pre-existing Zig-zag HFs from the same mice (white bracket), and Zig-zag HFs from wild-type-phenotype control mice (Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^) (n = 3 mice for each genotype; 34 de novo, 314 old/pre-existing, and 437 control HFs; [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Hair shaft length was measured in telogen stage hair shafts from the hair club to the HF opening (as indicated by the blue and white brackets). Left panel: Each dot represents a hair shaft and the dots are colored according to the HF type (blue for de novo HFs, gray for pre-existing Zig-zag HFs, orange for control Zig-zag HFs). De novo hair shafts were significantly smaller (p-value\<1.10^−6^) and thinner (p-value\<1.10^−6^) compared to old/pre-existing and control Zig-zag hairs (Mann-Whitney U test). Arrowheads on the x- and y-axis indicate the mean values of hair shaft length and width of de novo, old/pre-existing or control Zig-zag HFs, respectively. TD: touch dome. HF: hair follcile. TAM: tamoxifen. BF: bright field. Scale bars: 100 μm (**A**), 50 μm (**B, C**).\
Figure 2---source data 1.Quantification of hair width and length.Data are grouped according to hair type and mouse genotype.](elife-46756-fig2){#fig2}

To verify that these HFs were de novo induced, thorough examination of the Tomato lineage tracing pattern was of key importance. The *Gli1*-positive HF and TD populations self-renew independently with a clear *Gli1*-negative gap in the infundibulum ([Figure 1E](#fig1){ref-type="fig"}; [@bib37]). Cell crossover only occurs for example in response to full-thickness wounding or TPA treatment ([@bib8]; [@bib18]). Importantly, *Ptch1* deletion did not trigger HF cell migration towards the IFE or TD as we never observed Tomato-tracing spanning from a pre-existing HF -- via the infundibulum -- to the IFE or TD in any control or Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ skin ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). A non-traced infundibulum, leaving a tracing gap between the HF and the IFE/TD, is thus characteristic for pre-existing HFs. In contrast, all de novo HFs displayed continuous Tomato-tracing from the de novo HF to its originating TD, including the infundibulum and all anagen HF lineages ([Figures 1I](#fig1){ref-type="fig"} and [2A](#fig2){ref-type="fig"}, [Figure 1---video 1](#fig1video1){ref-type="video"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). As such a continuous HF-to-TD-tracing pattern can only result from newly formed HFs originating from traced TD-epithelial cells, we unequivocally demonstrated that these HFs were new.

An additional characteristic of de novo HFs was that their hair shafts were considerably shorter and thinner than hair shafts from both pre-existing HFs in the same mice (Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^) and HFs in control mice with wild type phenotype (Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^) ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). In conclusion, the continuous lineage-tracing from HF to TD, and the characteristic hair shaft measurements, demonstrated that combined epithelial and stromal Hh-pathway activation in the Gli1 mouse model via homozygous *Ptch1* inactivation resulted in de novo HFs, within TDs.

De novo HF formation recapitulates embryonic HF development {#s2-3}
-----------------------------------------------------------

Next we characterized the stages of de novo HF development in TDs equivalent to the embryonic HF developmental stages of HF placode, hair germ, hair peg and mature follicle ([@bib28]). We analyzed Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ and control skin, tamoxifen treated at 8 weeks of age, and collected samples 10, 17, 25, 27, 29, 33, 35 and 36 days after tamoxifen treatment. These sampling time points enabled us to map the entire stereotypical time course of de novo HF formation ([Figure 3A--D](#fig3){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). In some TDs, the HF-placode stage could be already detected 10 days post tamoxifen administration, and was accompanied by the appearance of a dermal condensate ([Figure 3A](#fig3){ref-type="fig"}). The dermal condensate and dermal papillae were delineated by denser Tomato-tracing of stromal cells compared to adjacent traced K5+ epithelial cells. Note the lack of continuous pre-existing HF-to-TD tracing at this early developmental stage ([Figure 3A,E](#fig3){ref-type="fig"}), again supporting that the fully traced HFs ([Figures 1I](#fig1){ref-type="fig"}, [2A](#fig2){ref-type="fig"} and [3B--D](#fig3){ref-type="fig"}) were newly formed and induced from traced TD cells. The hair germ and hair peg stages were mostly detected between 27 and 29 days post tamoxifen administration ([Figure 3B,C](#fig3){ref-type="fig"}), and mature HFs, with a clearly visible developing hair shaft, emerged mainly at or after 33 days post tamoxifen administration ([Figure 3D,D',F](#fig3){ref-type="fig"}). Interestingly, almost all dermal condensates and dermal papillae of de novo forming HFs were fully Tomato traced ([Figure 3A--D,F](#fig3){ref-type="fig"}), suggesting that either continuous high levels of Hh signaling in stromal cells (Ptch1^fl/fl^) are necessary for all stages of de novo HF development, or that stromal cells with constitutive Hh-pathway activation outcompete dermal condensate and dermal papilla cells with lower Hh-signaling levels. Importantly, Syndecan-1 (SDC1) expression that marks early dermal condensates in wild type embryonic skin ([Figure 4A](#fig4){ref-type="fig"}; [@bib29]), could already be detected 10 days post tamoxifen in dermal condensates of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ skin ([Figure 4B](#fig4){ref-type="fig"}), and was fully established in the dermal papilla at the hair germ stage ([Figure 4C](#fig4){ref-type="fig"}).

![Developmental stages of de novo hair follicles (HFs) in Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl ^touch domes (TDs).\
(**A--F**) Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice were treated with tamoxifen (TAM) at 8 weeks and dorsal skin was analyzed 10--36 days post TAM to characterize de novo HFs originating from TDs in the following developmental stages (n = 6 mice): early placode (**A**), hair germ (**B**), hair peg (**C**), and mature follicle (**D**). These stages recapitulate embryonic HF development ([@bib28]). Dermal condensates (**A, B**) or dermal papillae (**C, D**) are clearly visible, and the de novo HFs -- both early and mature -- are continuously traced into the TD. Note: HF-matrix cells are Tomato-traced with reduced intensity (\* in C), while the infundibulum of pre-existing HFs was not Tomato- traced (\*\* in D' and arrow in E). Furthermore, mature HFs contain a hair shaft (arrow in F). Inset in F shows K5-positive staining of the HF epithelial cells and a K5-negative dermal papilla. DC: dermal condensate. DP: dermal papilla. BF: bright field. Scale bars: 50 μm (**A-D**).](elife-46756-fig3){#fig3}

![SDC1 protein and *Gli1* mRNA expression in developing hair follicles (HFs).\
(**A**) In wild type embryonic skin (E15.5), Syndecan-1 (SDC1) staining highlights dermal condensates (DCs) (n = 2 mice). (**B--C**) Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice were treated with tamoxifen (TAM) at 8 weeks and dorsal skin was analyzed for SDC1 expression in the newly formed HF buds (n = 3 mice). (**B**) Early placode stage (image from a TD 10 days post TAM) displaying faint SDC1 staining in dermal condensate cells. Comparable to epithelium of wild type embryonic HF buds, early de novo placodes also express some SDC1. (**C**) Positive SDC1 staining of dermal papilla (image from a TD 4 weeks post TAM). (**D--E**) *Gli1* RNA-FISH. Both the epithelial placode and dermal condensate have active Hh/Gli signaling in wild type embryonic skin (E16.5) (**D**) and at lower levels in wild type TDs of adult skin (**E**). (**F--G**) Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice were treated with TAM at 8 weeks and dorsal skin was analyzed for *Gli1* mRNA expression in the placode stage (10 days post TAM) as well as in an intermediate developmental stage (5 weeks post TAM). Active canonical Hh/Gli signaling was present in all analyzed de novo HF stages in epithelial and dermal papilla cells. Note that Tomato-tracing was visualized using an RFP-antibody. Green and white dashed lines: epithelial-stromal border. Purple dashed line: outlines the dermal condensate. DC: dermal condensate. DP: dermal papilla. TD: touch dome. BF: bright field. For RNA-FISH stainings, n = 2 mice (**D, E and G**) and n = 1 mouse (**F**). Scale bars: 25 μm (**D--G**), 50 μm (**A-C, F-G** panoramas).](elife-46756-fig4){#fig4}

Finally, to demonstrate that these de novo HFs do indeed have active Hh signaling, we stained for *Gli1* mRNA expression; as a reporter of canonical Hh-pathway activity. The placodes (10 days post tamoxifen) as well as intermediate and mature developmental stages (5 weeks post tamoxifen) expressed *Gli1* mRNA and hence have active Hh/Gli signaling ([Figure 4F--G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C--D](#fig4s1){ref-type="fig"}); which is in line with normal embryonic HF development ([Figure 4D](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}; [@bib9]; [@bib35]). Wild type TD epithelial and stromal cells expressed *Gli1* mRNA as expected ([Figure 4](#fig4){ref-type="fig"}**E** and [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}).

This *Gli1* RNA-FISH combined with antibody staining for Tomato-lineage tracing also confirmed that Tomato-tracing (cells with *Ptch1* deletion) and *Gli1* expression were highly correlated, as expected ([Figure 4F--G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C--D](#fig4s1){ref-type="fig"}). We conclude that de novo HF formation in TDs of adult Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ skin recapitulates the hallmarks of HF development during embryogenesis.

De novo HFs persist while BCC-like tumors diminish upon vismodegib treatment {#s2-4}
----------------------------------------------------------------------------

De novo HF formation in the Gli1^creERT2^; R26^Tom^; Ptch1^fl/fl^ mouse model is accompanied with BCC growth; that is BCC-like lesions appear in pre-existing HF as well as in TDs ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). In TDs, the clearly identifiable de novo HFs develop alongside epithelial tumor growth which is characterized by palisading cells and lack of HF-like structures. It has been shown previously that BCC-like lesions in dorsal skin dramatically shrink within seven days upon vismodegib treatment ([@bib12]). Vismodegib is a Hh-pathway inhibitor acting at the level of Smoothened (Smo), and using the optimized treatment scheme from [@bib12] we tested whether established de novo HFs would persist or would diminish as the BCC-tumor-growth area does. We treated Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice with tamoxifen at 8 weeks. Five to seven weeks after tamoxifen treatment when de novo HFs were clearly established in TDs, we took a dorsal biopsy prior to vismodegib treatment (untreated biopsy), and then treated the mice daily with vismodegib (50 mg/kg body weight i.p.) for seven days ([Figure 5A](#fig5){ref-type="fig"}).

![Established de novo hair follicles (HFs) in touch domes (TDs) persist upon short-term vismodegib treatment.\
(**A**) Experimental scheme of vismodegib treatment. Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice were treated with tamoxifen (TAM) at 8 weeks of age. Five to seven weeks post TAM treatment, when de novo HFs were clearly established in the TDs, vismodegib was given daily for a week and dorsal skin was analyzed (n = 3 mice for Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^, n = 1 mouse for Gli1^creERT2^;Ptch1^fl/fl^). (**B**) Hematoxylin and eosin stainings showing that basal cell carcinoma (BCC)-like lesions were considerably reduced in response to a week of daily vismodegib treatment at a dose of 50 mg/kg body weight. (**C**) Tumor-cell proliferation in bulge area of pre-existing HFs assessed by Ki67 immunostaining. Bulge areas of untreated control biopsies showed high proliferation, which was almost entirely stalled in 7-day vismodegib samples; in the HF, only the sebaceous glands retained Ki67 expression. (**D**) BCC-like lesions were present in the TDs of dorsal biopsies taken prior to vismodegib treatment (left panel). In response to vismodegib, the tumor-growth area was considerably reduced while de novo HFs presisted (arrow). The de novo HFs are fully Tomato-traced and have a clearly visible hair shaft (arrowhead). HF: hair follicle. K8: marking TD area. Ki67: marking proliferating cells. TAM: tamoxifen. BF: bright field. Scale bars: 200 μm (**B** panaroma), 50 μm (**B** inset, **C, D**).](elife-46756-fig5){#fig5}

Reassuringly, in pre-existing HFs we found considerable reduction of tumor size ([Figure 5B](#fig5){ref-type="fig"}) as well as absence of Ki67 staining in Tomato-traced areas when comparing 7 day vismodegib treated samples with the untreated biopsies of the same mice ([Figure 5C](#fig5){ref-type="fig"}). This reduction in tumor size demonstrated that vismodegib treatment worked as expected. In TDs, the tumor areas also dramatically diminished in size and Ki67 staining, however the de novo HFs persisted ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In conclusion, these experiments confirmed that de novo HFs indeed represent HFs that are independent of tumor structures as they persist upon vismodegib treatment when the surrounding BCC-tumor-growth areas are nearly gone.

Stromal Hh-pathway activation alone is not sufficient to induce HF neogenesis {#s2-5}
-----------------------------------------------------------------------------

De novo HFs were induced by strong activation of Hh signaling (Ptch1^fl/fl^) in epithelial and adjacent stromal cells and persisted upon vismodegib treatment when the surrounding BCC-growth areas were nearly gone. As BCC growth merely depends on epithelial Hh-pathway activation, it was tempting to test whether homozygous inactivation of *Ptch1* exclusively in stromal cells would be sufficient to induce de novo HFs without tumor development. To that end, we generated the Col1a2 mouse model (Col1a2-Cre^ER^;R26^tdTomato^;Ptch1^fl/fl^, hereafter: Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^) ([Figure 6A,B](#fig6){ref-type="fig"}), which drives supra-physiological Hh signaling in the stromal compartment only, via the collagen type I alpha two chain promoter. Non-tamoxifen controls (Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ mice) showed some tracing in the skin stroma, which however did not result in an adverse skin phenotype except for earlier anagen entry ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Administration of tamoxifen at 8 weeks of age resulted in substantial Tomato-tracing that was restricted to the stromal skin compartment ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), and importantly, the stromal cells of the TD were also traced ([Figure 6D](#fig6){ref-type="fig"}). Homozygous *Ptch1* inactivation in *Col1a2*-expressing cells resulted in increased stromal cell density in TDs ([Figure 6E](#fig6){ref-type="fig"}), but did not result in de novo HF formation ([Figure 6C,E](#fig6){ref-type="fig"}), nor did stromal cells stain positive for SDC1 even 9 weeks after tamoxifen treatment ([Figure 6F](#fig6){ref-type="fig"}). We also detected fully traced and highly condensed dermal clusters of cells (resembling dermal condensates) in TD-adjacent infundibula and underneath the regular IFE ([Figure 6G](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}), which did not result in de novo HF induction and the dermal cell condensations were entirely negative for SDC1 expression ([Figure 6G](#fig6){ref-type="fig"}). We conclude that stromal activation of Hh signaling (Ptch1^fl/fl^) leads to increased stromal cell density and formation of cell condensates, however it is not sufficient to induce HF neogenesis in TDs nor elsewhere in skin without adjacent epithelial Hh-pathway activation.

![Stromal Hh pathway activation alone is not sufficient to induce hair follicle (HF) neogenesis in the touch domes (TDs) of Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^skin.\
(**A**) Schematic representation of the Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ mouse model and the experimental timeline. (**B**) Illustrative cartoon of Tomato-tracing of *Col1a2*-expressing cells and Hh-signaling levels in TD epithelium and TD stroma in this mouse model. (**C**) Quantification of de novo HFs in the TDs of Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ mice treated with tamoxifen (TAM) at 8 weeks. Dorsal skin was analyzed 9 weeks post TAM treatment (n = 3 mice). No de novo HFs were observed. (**D--G**) Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ and Col1a2^creER^;R26^Tom^;Ptch1^fl/wt^ control mice were treated with TAM at 8 weeks and dorsal skin was analyzed 10 days, 5 weeks, and 9 weeks after TAM treatment (n = 3 mice per genotype and time point). (**D**) TDs of mice with heterozygous *Ptch1* deletion were phenotypically normal. (**E**) TDs of mice with homozygous *Ptch1* inactivation did not develop de novo HFs. Frequently, a higher cell density in stroma was observed. (**F--G**) Syndecan-1 (SDC1) staining was negative in the condensed stroma of TDs (**F**) as well as in dermal cell condensations (arrows) underneath the IFE and HF infundibula (**G**) in Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ mice. TD: touch dome. HF: hair follcile. IFE: interfollicular epidermis. DC: dermal cell condensation. Scale bars: 50 μm (**D--G**).](elife-46756-fig6){#fig6}

Only TDs of the Gli1 mouse model are competent for HF initiation {#s2-6}
----------------------------------------------------------------

To directly compare all three different mouse models (Lgr6^creERT2^/, Gli1^creERT2^/, Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^) in their competence to initiate de novo HFs, we analyzed TDs 10 days post tamoxifen administration, the time point when epithelial proliferation became evident via, for example, increased BrdU incorporation in hair-forming TDs before appearance of morphological hair germ formation ([Figure 7](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). We investigated the stromal TD compartment using the alkaline phosphatase (AP) assay and SDC1 staining, which are both characteristic for HF-inducing dermal condensates ([@bib16]; [@bib29]). Positive staining for both alkaline phosphatase (ALPL) and SDC1 expression was observed in the Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice, but not in Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^, Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^, or Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ mice ([Figure 7A,B](#fig7){ref-type="fig"}). The epithelial TD compartment could not be stained for a comparable marker of early HF induction, as early BCC buds express typical HF-lineage markers. Indeed, we and others have not found a single mRNA/protein stain that would distinguish HF epithelial placode from BCC formation ([@bib18]; [@bib38]; [@bib40]). Altogether, staining for early signs of HF formation demonstrated that only the Gli1 (Ptch1^fl/fl^) model bears TDs that are competent for de novo HF formation.

![Expression of markers indicative for hair follicle (HF)-induction competent stroma in Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl ^touch domes (TDs).\
(**A--B**) Mice were treated with tamoxifen (TAM) at 8 weeks and dorsal skin was analyzed 10 days later using the alkaline phosphatase (AP) enzymatic assay (A; n = 2--3 mice per genotype) or Syndecan-1 (SDC1) immunofluorescence staining (B; n = 3 mice per genotype). (**A**) The TD stroma of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ skin stained AP-positive, indicating pre-dermal condensate formation. Please note that the nuclear staining (DAPI) in the areas of AP-positive signal is present but very dim (quenched). The TD stroma in skin of Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^, Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ and Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ stained AP-negative. (**B**) TD stroma of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ skin was clearly positive for SDC1 staining, while the TD stroma of Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ skin showed very weak to negative SDC1 staining. In the TDs of Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ and Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ skin, SDC1 staining was absent. Gu: Guard hair. TAM: tamoxifen. BF: bright field. Asterisks: sebaceous glands stain positive for AP. Arrowheads: positive AP-staining in TD stroma. Dashed line: epithelial-stromal border. Scale bars: 50 μm (**A--B**).](elife-46756-fig7){#fig7}

Cells outside TD niches can give rise to de novo HFs {#s2-7}
----------------------------------------------------

We established that de novo HF formation required close apposition of epithelial and stromal Hh signaling (Ptch1^fl/fl^), and furthermore how to identify de novo HFs based on their morphology and continuous lineage tracing. We next asked whether de novo HFs could also form from non-TD areas with comparable adjacent epithelial-stromal Hh-pathway activation.

In addition to TDs, the HF isthmus also harbors adjacent epithelial and stromal *Gli1*-Tomato traced cells; the latter evident through Tomato/PDGFRb co-staining of stromal cells ([Figure 8A,B](#fig8){ref-type="fig"}). Thus, we re-examined the HF isthmus areas of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ skin for potential de novo HFs. Indeed, at low frequency, we observed de novo HFs in the isthmus of pre-existing HFs that were most likely newly formed ([Figure 8C,D](#fig8){ref-type="fig"}). Although it was not possible to unequivocally determine de novo formation through continuous Tomato-tracing of the infundibulum (as these de novo HFs seem to merge directly into the isthmus area of pre-existing HFs), based on their morphology, positioning and the co-occurrence of four hair shafts instead of normally three (in dorsal skin of 17 week-old mice), these HFs likely formed newly from the isthmus of pre-existing HFs ([Figure 8C](#fig8){ref-type="fig"}). Such HFs have not been observed in phenotypically normal control skin (Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ and Lgr6^creERT2^;R26^Tom^;Ptch1^fl/wt^) or in skin with HF tumors (Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^) ([Figure 8D](#fig8){ref-type="fig"}). Reassuringly, in the HF isthmus *Lgr6* expression is restricted to epithelial cells only, whereas *Gli1* is expressed in epithelial and adjacent stromal cells ([@bib13]); suggesting that adjacent epithelial-stromal Hh signaling in areas outside of the TD may form de novo HFs.

![De novo hair follicle (HF) formation in isthmus area of pre-existing HFs.\
(**A--B**) PDGFRb (CD140b antibody) staining of Gli1^creERT2^;R26^Tom^ mice, treated with tamoxifen (TAM) at 8 weeks of age and traced for 2 weeks. Tomato-traced PDGFRb+ stromal cells are present in the HF isthmus area (**A**) and in the touch dome (TD) (**B**). (**C--D**) Mice were treated with TAM at 8 weeks of age and dorsal skin was analyzed 9 weeks post TAM. (**C**) Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ dorsal skin. Left panel: HFs without de novo HF contain three hair shafts (3 rounds of anagen). Right panel: HFs with de novo HF often contain four hair shafts including one thinner hair shaft with bent shape (arrowhead). (**D**) Quantification of de novo HFs in the isthmus area of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ (n = 668 HFs from n = 3 mice), Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ (n = 207 HFs from n = 3 mice), Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ (n = 335 HFs from n = 3 mice) and Lgr6^creERT2^;R26^Tom^;Ptch1^fl/wt^ (n = 83 HFs from n = 3 mice) ([Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"}). De novo HFs were only detected in isthmus areas of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice. p-value=0.09 (t-test comparing Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ and Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^). n = 3 mice (**A--C**). dnHF: de novo hair follicle. TAM: tamoxifen. BF: bright field. Scale bars: 20 μm (**A**), 10 μm (**B**), 50 μm (**C**).\
Figure 8---source data 1.Quantification of de novo hairs from isthmus.Data are grouped according to mouse genotype.](elife-46756-fig8){#fig8}

Epithelial and adjacent stromal Hh-pathway activation induces de novo HF formation in hairless paw skin {#s2-8}
-------------------------------------------------------------------------------------------------------

The mouse hindpaw (plantar) epidermis is a skin region devoid of hair follicles and sweat glands, and is therefore ideal to test whether epithelial and stromal Hh-pathway activation can induce de novo HFs divorced from any confounding effects of nearby HF- or TD-niche signals ([Figure 9A](#fig9){ref-type="fig"}). When we probed for *Gli1* expression in the plantar skin using *Gli1*^LacZ^ reporter mice, we consistently found small *Gli1*-BGAL expressing clusters of epithelial and adjacent stromal cells in the plantar skin ([Figure 9B](#fig9){ref-type="fig"}, [Figure 9---figure supplement 1A](#fig9s1){ref-type="fig"}), which we confirmed with short-term lineage tracing in Gli1^creERT2^;R26^Tom^ mice (tamoxifen at P8w; sample collection 7 days later) ([Figure 9C](#fig9){ref-type="fig"}, [Figure 9---figure supplement 1B](#fig9s1){ref-type="fig"}). Therefore, the plantar skin was a suitable area for studying if de novo HFs can form in the Gli1 mouse model upon homozygous *Ptch1* inactivation.

![Formation of de novo hair follicles (HFs) in the plantar skin of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice.\
(**A**) Illustrative cartoon of a mouse hindpaw. (**B**) *Gli1*^LacZ^ expression in the plantar skin (n = 3 mice). (**C**) Gli1^creERT2^;R26^Tom^ mice were treated with tamoxifen (TAM) at 8 weeks of age. The hindpaws were collected 1 week post TAM and immuno-stained with K5 antibody (n = 3 mice). Asterisks mark autofluorescence on the outermost keratinized layer. (**D--E**) Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ and control Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ mice were treated with TAM at 8 weeks of age. Hindpaws were collected 5 or 9 weeks post TAM (n = 3 mice for each genotype; except n = 2 for Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ 5 weeks post TAM ). (**D**) Numerous de novo HFs formed in the plantar skin of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice, while the same skin region in the control mice remained phenotypically normal. Green and black frames: zoom-in of plantar epidermis. Hematoxylin and eosin stained. (**E**) De novo HF structure in plantar skin of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice are fully Tomato-traced and contain a K6+ companion layer as well as hair shafts (n = 2 mice). Arrowheads: de novo hair shafts. Arrows: dermal papilla. Cp: companion layer. Dashed line: epithelial-stromal border. TAM: tamoxifen. BF: bright field. Scale bars: 20 μm (**B--C**), 500 μm (**D** panaromas), 50 μm (**D, E** insets).](elife-46756-fig9){#fig9}

Testing for de novo HF induction, we analyzed the hindpaws of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice and control littermates (Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^) using the same treatment scheme and sample collection times as for dorsal skin (tamoxifen at P8w; sample collection 5 and 9 weeks post tamoxifen; additional time points see [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Indeed, we found numerous de novo HFs with hair shafts in the normally hairless region. These HFs were fully Tomato-traced and showed normal inner-layer differentiation based on morphology and K6 staining ([Figure 9D--E](#fig9){ref-type="fig"}, [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}).

Taken together, the analysis of dorsal HF-isthmus as well as hairless paw skin demonstrated that combined epithelial and stromal Hh-pathway activation can induce de novo HFs independently of TD niches.

Discussion {#s3}
==========

Hitherto, hair follicle neogenesis in adult skin had only been observed under exceptional circumstances, such as upon repair of large wounds ([@bib6]; [@bib16]). A recent study found that it is possible to induce HFs even in small wounds upon supra-physiological Hh-pathway activation in the wound stroma ([@bib21]). This report and our present study recognize modulation of Hh signaling as a new approach to induce de novo HFs in adult skin, and define activation in the stromal skin compartment as critical. As wounding of skin initiates a major reorganization of the epithelial and mesenchymal tissue including the activation and differentiation of a large number of cell types ([@bib3]; [@bib17]; [@bib31]), and may even provide an embryonic-like environment ([@bib36]), the precise (e.g. minimal) molecular signals that are required for HF induction in adult skin remain elusive. Here we revealed that in unwounded skin, experimentally elevated Hh signaling in epithelial and adjacent stromal cells was sufficient to induce de novo HFs, extending our understanding of how Hh signaling can be modulated to induce HFs in adult skin.

To achieve efficient de novo HF induction in unwounded skin, supra-physiological Hh signaling in both compartments, the epithelium and stroma, was necessary. Normal TD maintenance also requires active and balanced Hh signaling in adjacent epithelial and stromal cells ([Figure 4E](#fig4){ref-type="fig"}; [@bib37]). Increased Hh-signaling levels in TD epithelial cells result in BCC-like tumors, even though stromal cells have active (albeit physiological) Hh signaling. Only in extremely rare cases (twice) did we detect a de novo HF-like structure in TDs of Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice based on morphology (as lineage tracing in these mice cannot provide information on de novo HF formation; [Figure 1H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Importantly therefore, to effectively induce de novo HFs in TDs, high levels of Hh/Gli signaling in both compartments were necessary (Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^). This requirement of Hh-signal activation at precise levels and in the right compartments is in agreement with a recent study demonstrating that β-catenin-induced de novo HF formation was not only dependent on stromal Hh signaling, but also required two intact *Smo* alleles (for a maximal Hh-pathway activation) to enable efficient de novo HF induction ([@bib20]).

It has been shown more than twenty years ago that the activation of epithelial β-catenin in mouse skin can induce new HFs ([@bib14]; [@bib22]), and more recently that activation of epithelial Wnt/β-catenin signaling increases de novo HF formation within wounds ([@bib16]). However, Wnt signaling has to be blocked in dermal fibroblasts to allow de novo HF induction during wound regeneration ([@bib30]). It is known that early stage BCCs resemble early stages of HF development and both are dependent on Wnt- and Hh-pathway activation, with the major morphological difference that BCC lacks a dermal condensate ([@bib38]). Learning from abrogated embryonic HF development ([@bib35]) led us to hypothesize that simultaneously activating supra-physiological Hh signaling in the stroma underneath developing BCC may enable de novo HFs. Indeed, by coordinating the activation of Hh/Gli signaling (cell type specific and high levels) we were able to induce de novo HFs by 'redirecting' some of the BCC buds to HF formation without the need of wounding. Nevertheless, this induction occurred in the presence of oncogenic signal activation (i.e. presence of a tumor environment or tumor-like cellular status of Ptch1^fl/fl^ HF-inducing epithelial cells) which may to some extent mimic a wounding situation ([@bib11]).

The molecular and cellular similarities of tumorigenesis and wound healing are still unfolding, yet whenever de novo HFs were to be found, either oncogenic signaling or a wound environment was involved. This supports the long-standing recognition of the similarity between tumor and wound healing signaling (tumors as 'wounds that do not heal') -- and raises the key question of what exactly is the relationship between tumorigenesis and signals inducing de novo HF formation? It may indeed be the case that in order to overcome inhibitory signals, de novo HF morphogenesis in adult skin requires such major activating signals provided by oncogenesis or wounding. Interestingly however, previous literature suggests that only initial HF placode and/or dermal condensate formation may require such strong signals whereas progression to a mature HF does not require continued tumorigenic or wound signaling ([@bib7]; [@bib16]; [@bib22]; [@bib33]). For example, HF tumors require continuous Wnt/β-catenin signaling, whereas transient activation of this pathway is sufficient to induce de novo HFs in adult mouse epidermis ([@bib22]). More recently, intra vital imaging from Wnt/β-catenin induced tumor outgrowths demonstrated that non-mutant cells, remaining from regressed outgrowths, could develop into new functional HFs. Most interestingly, tumor outgrowth depended on the presence of mutated cells, however the new appendages were formed from wild type cells facilitated by their (altered) niche environment ([@bib7]). Taken together, these are promising examples that de novo HF induction without accompanied tumor growth in unwounded adult skin may in principle be possible, if the right signals at the right time and restricted period, and in the right compartments were provided. Here, we spatiotemporally defined such productive and specific molecular signals.

Lastly, and importantly, we exploited the hairless paw plantar skin to examine de novo HF morphogenesis in the absence of confounding signals from pre-existing HFs or TDs. Strikingly, we observed numerous de novo HFs throughout this nominally hairless skin in Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice. Crucially, nearly all these de novo HFs developed without attendant BCC-like lesions suggesting that de novo HF morphogenesis may indeed be successfully initiated without a tumor microenvironment; while the vismodegib experiment suggests persistence of such structures when the tumor microenvironment regresses in dorsal skin. Examining these two divergent tissues in molecular detail, one permissive (dorsal) and one suppressive (paw) to dual BCC and HF induction, could therefore be a next step of unraveling the complexity of how these heterogeneous signals interact.

In sum, molecular strategies for the induction of complex epithelial structures in the adult remain a major challenge in regenerative medicine. Our study demonstrates that cell-type specific modulation of a single pathway was sufficient to induce complex epithelial structures in the adult body, a discovery aiding our understanding of adult tissue biology and regenerative medicine.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                       Source or reference                           Identifiers                                                              Additional\
  (species) or resource                                                                                                                                                                                      information
  --------------------------------- ------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------
  Genetic reagent (*M. musculus*)   Lgr6-EGFP-IRES-CreERT2                            [@bib34]                                      Jackson Labs stock no: 016934\                                           Received from H Clevers
                                                                                                                                    RRID:[IMSR_JAX:016934](https://scicrunch.org/resolver/IMSR_JAX:016934)   

  Genetic reagent (*M. musculus*)   Gli1-LacZ                                         [@bib4]                                       Jackson Labs stock no: 008211\                                           Received from F Aberger
                                                                                                                                    RRID:[IMSR_JAX:008211](https://scicrunch.org/resolver/IMSR_JAX:008211)   

  Genetic reagent (*M. musculus*)   Gli1-CreERT2                                      [@bib1]                                       Jackson Labs stock no: 007913\                                           Received from F Aberger
                                                                                                                                    RRID:[IMSR_JAX:007913](https://scicrunch.org/resolver/IMSR_JAX:007913)   

  Genetic reagent (*M. musculus*)   Col1a2-CreER                                      [@bib41]                                      Jackson Labs stock no: 029567\                                           Received from B Crombrugghe
                                                                                                                                    RRID:[IMSR_JAX:029567](https://scicrunch.org/resolver/IMSR_JAX:029567)   

  Genetic reagent (*M. musculus*)   R26-tdTomato                                      [@bib23]                                      Jackson Labs stock no: 007908\                                           Obtained from Jackson Laboratory
                                                                                                                                    RRID:[IMSR_JAX:007908](https://scicrunch.org/resolver/IMSR_JAX:007908)   

  Genetic reagent (*M. musculus*)   Ptch1neo(fl)Ex2(fl)                               [@bib18]                                                                                                               Received from S. Teglund

  Genetic reagent (*M. musculus*)   C57BL/6J                                                                                        Jackson Labs stock no: 000664\                                           Received from Preclinical Laboratory Karolinska Institutet
                                                                                                                                    RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)   

  Antibody                          Rabbit polyclonal anti-K5                         BioLegend                                     Cat\# PRB-160P\                                                          (1:1000)
                                                                                                                                    RRID:[AB_291581](https://scicrunch.org/resolver/AB_291581)               

  Antibody                          Guinea pig polyclonal anti-K5                     US Biological                                 Cat\# C9097-37\                                                          (1:50)\
                                                                                                                                    RRID:[AB_2134285](https://scicrunch.org/resolver/AB_2134285)             (1:200 for RNA-FISH)

  Antibody                          Rat monoclonal anti-SDC1                          BD Biosciences                                Cat\# 553712\                                                            (1:500)
                                                                                                                                    RRID: [AB_394998](https://scicrunch.org/resolver/AB_394998)              

  Antibody                          Rat monoclonal anti-K8                            DSHB (Developmental Studies Hybridoma Bank)   Cat\# TROMA-I\                                                           (1:1000)
                                                                                                                                    RRID:[AB_531826](https://scicrunch.org/resolver/AB_531826)               

  Antibody                          Rabbit polyclonal anti-K6                         BioLegend                                     Cat\# PRB-169P\                                                          (1:2000)
                                                                                                                                    RRID:[AB_10063923](https://scicrunch.org/resolver/AB_10063923)           

  Antibody                          Guinea pig polyclonal anti-K71                    Progen                                        Cat\# GP-K6irs1\                                                         (1:100)
                                                                                                                                    RRID:[AB_2716781](https://scicrunch.org/resolver/AB_2716781)             

  Antibody                          Rabbit polyclonal anti-RFP                        Rockland                                      Cat\# 600-401-379\                                                       (1:100)
                                                                                                                                    RRID:[AB_2209751](https://scicrunch.org/resolver/AB_2209751)             

  Antibody                          Rat monoclonal anti-BrdU                          Serotec                                       Cat\# OBT0030G\                                                          (1:400)
                                                                                                                                    RRID: [AB_609567](https://scicrunch.org/resolver/AB_609567)              

  Antibody                          Rabbit polyclonal anti-GFP                        Thermo Fisher Scientific                      Cat\# A-11122\                                                           (1:500)
                                                                                                                                    RRID:[AB_221569](https://scicrunch.org/resolver/AB_221569)               

  Antibody                          Rabbit polyclonal anti-Ki67                       Abcam                                         Cat\# ab15580\                                                           (1:200)
                                                                                                                                    RRID:[AB_443209](https://scicrunch.org/resolver/AB_443209)               

  Antibody                          Rat monoclonal anti-CD140b                        BioLegend                                     Cat\# 136008\                                                            (1:100)
                                                                                                                                    RRID:[AB_2268091](https://scicrunch.org/resolver/AB_2268091)             

  Chemical compound, drug           TO-PRO-3                                          Invitrogen                                    Cat\# T3605                                                              (1:1000)

  Chemical compound, drug           Hoechst 33342                                     Invitrogen                                    Cat\# H3570                                                              (1 µg/mL)

  Chemical compound, drug           DAPI                                              Invitrogen                                    Cat\# D1306\                                                             (1 µg/mL)

  Chemical compound, drug           Tamoxifen                                         Sigma                                         Cat\# T5648                                                              

  Chemical compound, drug           4-OH Tamoxifen                                    Sigma                                         Cat\# H6278                                                              

  Chemical compound, drug           NBT/BCIP stock solution                           Roche                                         Cat\# 11681451001                                                        

  Chemical compound, drug           Vismodegib, Free Base                             LC Laboratories                               Cat\# V-4050                                                             

  Commercial assay or kit           RNAscope Multiplex Fluorescent Kit v2             ACDBio/Bio-Techne                             Cat\# 323100                                                             

  Commercial assay or kit           TSA Cy 3, Cy 5, TMR, Fluorescein Evaluation Kit   Perkin Elmer                                  Cat\# NEL760001KT                                                        

  Sequence-based reagent            3-plex Positive Control Probe                     ACDBio/Bio-Techne                             Cat\# 320881                                                             RNA-FISH Probe

  Sequence-based reagent            3-plex Negative Control Probe                     ACDBio/Bio-Techne                             Cat\# 320871                                                             RNA-FISH Probe

  Sequence-based reagent            Mm-Gli1                                           ACDBio/Bio-Techne                             Cat\# 311001                                                             RNA-FISH Probe
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse models and treatments {#s4-1}
---------------------------

Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice and control littermates, and Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice and control littermates were treated with tamoxifen at second telogen (mice aged 8 weeks, 6 mg tamoxifen i.p. in corn oil, 20 mg/mL). Dorsal samples were taken at different time points after tamoxifen treatment (as indicated in the text), and were obtained via 3--4 mm full thickness biopsies or by sacrificing the animal (n ≥ 3 mice for each genotype; for details please see [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Some of the Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ mice, when receiving the same treatment as the Gli1 and Lgr6 models as described above, developed within a few weeks a severe intestinal phenotype, precluding comparative skin analysis at 5 and 9 weeks post tamoxifen administration. Thus Col1a2^creER^;R26^Tom^;Ptch1^fl/fl^ mice and control littermates were treated at second telogen topically or with a reduced amount of tamoxifen i.p. (mice aged 8 weeks, 2 × 0.75 mg 4-OH tamoxifen topically or 3 mg tamoxifen i.p. in corn oil, 20 mg/mL; [Supplementary file 1](#supp1){ref-type="supplementary-material"}), and some were treated at first telogen (mice aged 3 weeks, 1 mg tamoxifen i.p. in corn oil, 20 mg/mL). Samples were harvested at different time points after tamoxifen treatment (as indicated in the text). More details of analyzed mice, including control mouse experiments, treatments, and phenotypes, are given in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. For BrdU incorporation, mice were injected i.p. with BrdU (Sigma) solution (10 mg/ml). A dose of 0.1 mg/g body weight was administered 2 hr prior to sacrifice. For vismodegib treatment, the Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice and control littermates Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ were treated with tamoxifen at 8 weeks of age. Five to seven weeks after tamoxifen treatment, when de novo HFs were clearly established in TDs, a dorsal biopsy prior to vismodegib treatment was taken. From then, the vismodegib was given daily (50 mg/kg body weight i.p.) for a week and dorsal samples were collected for further analysis (n ≥ 3 mice). Embryos were collected at E15.5 and E16.5, and wild-type control samples for dorsal tissue were collected at postnatal day 27 and week 9. All mouse experiments were performed in accordance to Swedish legislation and approved by the Stockholm South or Linköping Animal Ethics Committees.

Tissue staining, microscopy and image analysis {#s4-2}
----------------------------------------------

All antibodies, β-Galactosidase, alkaline phosphatase (AP), and RNA-FISH stainings were performed on either mouse dorsal skin or hindpaw samples as described below (1-5). For nuclear stains, TO-PRO-3, Hoechst 33342 or DAPI (all from Invitrogen) were used in the different applications below (1-4).

\(1\) Immunofluorescence (IF) staining on formalin-fixed, paraffin-embedded (FFPE) sections. After de-waxing and antigen retrieval in 10 mM citrate buffer or Diva Decloaker (Biocare Medical) for approximately 20 min in a pressure cooker (2100 Retriever), the sections were blocked with serum and then incubated with primary antibodies specific for K5 (rabbit 1:1000), Syndecan-1 (1:500). Secondary antibodies were Alexa Fluor Dyes (Invitrogen, 1:500). Used in [Figure 4A](#fig4){ref-type="fig"}.

\(2\) Horizontal whole mount (HWM) IF staining. Samples of dorsal skin were fixed in 4% PFA for 20 min and mounted in OCT embedding medium (Histolab). Subsequently, 60--150 μm sections were cut with a cryostat, blocked with PB buffer (0.1% fish skin gelatin, 0.5% Triton X-100% and 0.5% skimmed milk powder in PBS) and stained as described previously ([@bib10]). The nuclear stains were applied at the same time as secondary antibodies. Primary antibodies used: K8 (1:1000), K5 (rabbit 1:1000, guinea pig 1:50), K6 (1:2000), K71 (1:100), Syndecan-1 (1:500), GFP (1:500), BrdU (1:400), RFP (1:100), Ki67 (1:200), CD140b (1:100). Secondary antibodies used: Alexa Fluor Dyes 488, 546, 647 or 680 (Invitrogen, 1:500). Used in: [Figure 1D,F--I](#fig1){ref-type="fig"}; [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}, [2](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}; [Figure 2A,C](#fig2){ref-type="fig"}; [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"} and [2](#fig2s2){ref-type="fig"}; [Figure 3A--F](#fig3){ref-type="fig"}; [Figure 4B,C](#fig4){ref-type="fig"}; [Figure 5C,D](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}; [Figure 6D--G](#fig6){ref-type="fig"}; [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}; [Figure 7A,B](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}; [Figure 8A,B](#fig8){ref-type="fig"}; [Figure 9C,E](#fig9){ref-type="fig"}; [Figure 9---figure supplements 1B](#fig9s1){ref-type="fig"} and [2A--B](#fig9s2){ref-type="fig"}.

\(3\) RNA Fluorescent in situ hybridization (RNA-FISH). RNA-FISH for *Gli1 *was performed using the RNAscope Multiplex Fluorescent Detection Kit v2 according to manufacturer's instructions using TSA with Fluorescein on 4-10 μm FFPE sections. All sections were co-stained with anti-RFP (1:100) and anti-K5 (guinea pig 1:200) antibodies and counterstained with DAPI (1 μg/mL). Each co-staining was performed on two different mice for each time point, with the exception of only one mouse for the T10d time point. Used in: [Figure 4D--G](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.

\(4\) Alkaline phosphatase (AP) enzymatic assay. HWM skin samples were cut into 60--100 μm sections, fixed in acetone for 1 hr at 4°C, pre-incubated with NTMT solution (100 mM NaCl, 100 mM Tris-Cl pH9.5, 50 mM MgCl2, 0.1% Tween-20) at RT for 10 min and stained in NBT/BCIP solution (20 μL in 1 ml NTMT solution) for 1--3 min at 37°C. The reaction was stopped with 20 mM EDTA in PBS. The AP-stained tissue subsequently underwent HWM IF staining. Used in: [Figure 7A](#fig7){ref-type="fig"}.

\(5\) LacZ (β-Galactosidase) staining. Freshly obtained skin tissue was fixed (4% paraformaldehyde in PBS) for 30 min at RT. Tissues were washed for 15 min with rinse buffer (2 mM MgCl2, 0.01% Nonidet P-40 in PBS). Subsequently, the β-galactosidase substrate solution (1 mg/mL X-Gal, 5 mM K~3~Fe(CN)~6~, 5 mM K~4~Fe (CN)~6~·3H~2~O in rinse buffer) was added and the tissues were incubated for 18 hr at 37°C in the dark. The substrate was removed, and the tissues were washed twice in PBS for 10 min and kept in 70% ethanol until embedding (maximum 48 hr). The stained tissues were processed into paraffin blocks according to standard procedures. Tissue sections (4 μm) were prepared and counterstained with eosin or H&E. Used in [Figure 1E](#fig1){ref-type="fig"}; [Figure 9B](#fig9){ref-type="fig"}; [Figure 9---figure supplement 1A](#fig9s1){ref-type="fig"}.

Imaging was performed using a Leica (color bright-field images), LSM710-NLO confocal microscope (Zeiss) or Nikon A1R confocal microscope. Image analysis was performed using NIS-Elements software (Nikon), Zen 2009 software (Zeiss), or ImageJ, and images were occasionally optimized for brightness, contrast, and color balance. RNA-FISH images are presented as maximum intensity projections covering 6 μm of depth.

Measurements and quantitative image analysis of de novo hair follicles {#s4-3}
----------------------------------------------------------------------

Measurements of de novo and pre-existing Zig-zag HFs were performed in samples from Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ and Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ mice taken 9 weeks after tamoxifen treatment. Image J was used to analyze the images.

(1) Quantification of de novo HFs in touch domes. Touch domes were identified via Tomato-tracing and the presence of Merkel cells (K8+). Subsequently, all HFs and hair shafts were visualized with bright field images. Only telogen stage hairs that were fully visible from the bulge to the IFE opening were selected and used to measure their length (i.e. the distance from the bottom/hair club of the telogen hair shaft to the opening of the follicle in the IFE), and width (which was measured where the hair shaft meets the IFE); see [Figure 2C](#fig2){ref-type="fig"}. In total, de novo HFs were observed in all of the 27 analyzed touch domes (on average 2.6 de novo HFs per touch dome) in three different mice, and 34 hair shafts from 20 touch domes qualified for measurements. As controls, pre-existing Zig-zag hairs of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ (i.e. the same samples as for de novo HF measurements; n = 3 mice; 314 hairs in total) and Zig-zag hairs of Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ control mice lacking BCC and de novo HFs (n = 3 mice; 437 hairs in total) were analyzed in the same way ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}).

To statistically estimate whether the putative de novo HFs could merely represent small Zig-zag hairs, a bootstrapping approach was used: a random sample corresponding to the number of observed de novo HFs (n = 34) was taken from the distribution of observed Zig-zag hairs (n = 751) for 10.000.000 times, and the probability that this random sample is equal to or smaller in length and width than the de novo HFs was subsequently calculated.

(2) Quantification of de novo hairs in isthmus areas of pre-existing HFs. Quantification of de novo hairs in the isthmus area of HFs (note that we were not able to tell Zig-zag/Awl/Au HFs apart and collectively call them Zig-zag) was performed in samples from Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^, Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^, Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ and Lgr6^creERT2^;R26^Tom^;Ptch1^fl/wt^ mice (n = 3 for each genotype) taken 9 weeks after tamoxifen treatment. De novo hairs were identified by their relatively smaller size, growing pattern and/or there being more than three hairs in a pre-existing HF. De novo hairs growing from the isthmus area were only observed in the Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice with a total of 16 identified de novo hairs in 668 Zig-zag HFs. Gli1^creERT2^;R26^Tom^;Ptch1^fl/wt^ (335 HFs), Lgr6^creERT2^;R26^Tom^;Ptch1^fl/fl^ (207 HFs) and Lgr6^creERT2^;R26^Tom^;Ptch1^fl/wt^ (83 HFs) mice showed no de novo hairs from the isthmus area.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The revised manuscript by Sun and Are et al. contains a tour de force of new experiments aimed at showing where de novo hair follicle formation can occur in mouse skin and exploring whether these follicles are similar to existing follicles. The data and conclusions are quite convincing, highly relevant and impactful in the current skin field.

**Decision letter after peer review:**

Thank you for submitting your article \"Coordinated hedgehog signaling induces new hair follicles in adult skin\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Sun et al. use inducible reporter mice to show that localized Hedgehog signaling can induce de novo hair follicle formation in adult mice. They show that diffuse Hedgehog activation via loss of Ptch1 in the epidermis (Lgr6-CreERT2) or the dermis (Col1a2-CreER) does not induce de novo hair follicle formation, but a localized source of Hedgehog activation via loss of Ptch1 at the touch dome (Gli1-CreERT2) does. The hair follicles show at least some of the necessary layers of a fully formed structure such as the inner root sheath (Krt71) and outer root sheath (Krt6), and seem to be fully functional as they produce hair. The de novo follicles are also associated with dermal condensates (Sdc1 and Alpl), a structure necessary for placode formation and hair follicle growth. This work complements the work by Lim et al., 2018, who show that Hedgehog can stimulate de novo hair follicles during wound healing. This work is novel and would be of broad interest to the readers of *eLife* both in the instructive signals that organs need to develop (or regenerate) and as a potential way to induce de novo hair follicles in adult humans (if one gets past the concomitant induction of basal cell carcinoma).

Essential revisions:

1\) It would be interesting to discuss whether tumorigenic microenvironment or cellular status mimics wounding situations.

2\) Some parts in the manuscript including the Abstract may be misleading to provide an impression that the combination of epithelial and dermal Hh activation leads to HF, while epithelial Hh alone leads to tumor. The data shows that the Hh activation in both epidermal and dermal cells also results in BCC, but with hair follicle induction. Hair follicles are immature and abnormal and appear to be a part of the tumor. The authors should revise the text/Abstract to clearly indicate this important point.

3\) Since Lgr6+ epithelial cells are known as stem cells, do they form hair follicles upon Hh activation in unwounded skin regardless of TD environment? In Figure 1E, Lgr6+ epithelial cells exist beyond TD. What if Hh is activated in the Lgr6+cells outside of TD and underlying stroma using Lgr6^CreER^/Col1a2^CreER^/Ptch^fl/fl^?

4\) Do dermal condensates form only in the stroma of TD? If this is the case, the authors may be able to show that the TD area is specialized to form hair follicles.

5\) In Figure 1D, Gli1 is positive in follicular epithelium and surrounding stromal cells of guard hairs. When Hh is activated in Gli1/Tom/Ptch1^fl/fl^, did de novo hair follicles form in the Gli1+ area of guard hairs? It may help support that TD is a primed structure to form hair follicles in adult unwounded mouse skin.

6\) Although this work clearly shows that localized Hedgehog signaling can induce hair follicles, the equivalency of these structures to existing follicles and the lack of mechanism should be addressed as detailed below.

7\) The de novo hair follicles form under constant Hedgehog signaling, which is typically only active during the anagen phase of the hair follicle and is shut down to allow the hair follicle to proceed to catagen/telogen.

Do the de novo hair follicles cycle when induced with the Gli1-CreERT2 promoter?

8\) Is Hedgehog pathway activation necessary for de novo hair follicle formation or merely Ptch1 loss?

9\) Can the hair follicles persist without Hedgehog signaling?

Use of Smo inhibitors such as vismodegib can be helpful to answer these questions by administering the drug after tamoxifen injection or after the hair follicle has already formed.

10.7554/eLife.46756.sa2

Author response

> Essential revisions:
>
> 1\) It would be interesting to discuss whether tumorigenic microenvironment or cellular status mimics wounding situations.

Based on the reviewers suggestion, we have now discussed this important point that is now included within two new paragraphs in the Discussion section of the revised manuscript text. Overall, we have extensively revised the Discussion text, also accommodating new results and putting important other studies in context.

> 2\) Some parts in the manuscript including the Abstract may be misleading to provide an impression that the combination of epithelial and dermal Hh activation leads to HF, while epithelial Hh alone leads to tumor. The data shows that the Hh activation in both epidermal and dermal cells also results in BCC, but with hair follicle induction. Hair follicles are immature and abnormal and appear to be a part of the tumor. The authors should revise the text/Abstract to clearly indicate this important point.

We agree with the reviewers and we have now updated the Abstract and emphasize in the Results and in the Discussion that Hh activation in both epithelial and dermal cells also results in BCC.

> 3\) Since Lgr6+ epithelial cells are known as stem cells, do they form hair follicles upon Hh activation in unwounded skin regardless of TD environment? In Figure 1E, Lgr6+ epithelial cells exist beyond TD. What if Hh is activated in the Lgr6+cells outside of TD and underlying stroma using Lgr6^CreER^/Col1a2^CreER^/Ptch^fl/fl^?

In the light of the reviewers comments 3, 4 and 5, we made a large effort to address the overall question whether de novo HFs form specifically in touch domes, or if de novo HFs also can form from non-touch dome areas of the interfollicular epidermis (IFE), the hair follicle isthmus/bulge, and from the hairless epidermis of the hindpaw. The experiments and respective outcomes are described in detail here below and in response to comments 4 and 5.

1\) To directly address point 3, we crossed Lgr6^CreERT2^/Ptch1^fl/wt^ female with Col1a2^CreER^/Ptch1^fl/fl^ male mice (with a breeding probability of 1:8; Lgr6^CreERT2^/Ptch1^fl/wt^ males crossed with Col1a2^CreER^/Ptch1^fl/fl^ females did not result in viable litters), which gave in total four quadruple transgenic mice (Lgr6^CreERT2^/ Col1a2^CreER^/Ptch1^fl/fl^). We treated these four mice and littermate controls at postnatal week 8 (P8w) topically with 4-OH tamoxifen (TAM), and collected samples at time points post TAM treatment where we certainly would find small de novo HF buds or de novo HFs in the touch domes of Gli1^creER^/R26^Tom^/Ptch1^fl/fl^ mice. I.e. we collected dorsal skin (biopsies or entire back skin) 17 days and 31-49 days post TAM. At 17 days post TAM we observed many epithelial buds, predominantly located in the upper part of the infundibulum connecting to the IFE and occasionally in the IFE (n = 4 mice; biopsies) ([Author response image 1](#respfig1){ref-type="fig"}). These epithelial buds were most often surrounded with dermal cells that expressed SDC1, similar to the dermal condensate cells in de novo HF-forming Gli1^creER^/R26^Tom^/Ptch1^fl/fl^ mice ([Author response image 1B](#respfig1){ref-type="fig"}). Based on this observation we expected to find plenty of de novo HFs from the IFE/infundibulum area in 31-49 post TAM skin of the same mice, which however was not the case. Either not at all (n = 2 mice) or very rarely (n = 2 mice; 1 and 2 hair shafts, respectively), we observed a small hair shaft in the IFE/infundibulum area that was likely formed de novo based on its morphology, size and thickness. However, based on HF/bulge cell morphology these hair shafts seemed not properly anchored or even soon to be shed ([Author response image 1C](#respfig1){ref-type="fig"}). In the touch domes of Gli1^creER^/R26^Tom^/Ptch1^fl/fl^ mice, such HFs "without proper bulge anchoring" were never observed. As a control for de novo HF formation, we also analyzed the touch domes of the Lgr6^CreERT2^/Col1a2^CreER^/Ptch1^fl/fl^ mice and indeed found in every mouse a low number of touch domes that contained de novo HFs or hair shafts (based on morphology, size and thickness) ([Author response image 1D](#respfig1){ref-type="fig"}). I.e. in touch domes de novo HFs likely formed but with much lower efficiency than in Gli1^creER^/R26^Tom^/Ptch1^fl/fl^ mice.

In this regard, it is important to note that *Ptch1* inactivation in the skin stroma (i.e. in Col1a2^CreER^/Ptch1^fl/fl^ mice) leads shortly after TAM injection (i.p.) to an overall bad body condition of malnutrition due to an intestinal phenotype, which is less severe but still present with topical treatment (described in the Materials and methods section of the manuscript). Unfortunately, the quadruple transgenic Lgr6^CreERT2^/Col1a2^CreER^/Ptch1^fl/fl^ developed a more severe phenotype of malnutrition than Col1a2^CreER^/Ptch1^fl/fl^, which could of course negatively impact de novo HF development.

In sum, Lgr6^CreERT2^/Col1a2^CreER^/Ptch1^fl/fl^ had numerous de novo HF-like buds at the initial time point, however the occurrence of de novo HF/hair shafts at later time points was very low or not present. As Lgr6^CreERT2^/Col1a2^CreER^/Ptch1^fl/fl^ mice did not contain a Tomato lineage tracing allele, an unequivocal confirmation that these extremely rare HFs/hair shafts were indeed newly formed was not possible, thus these experiments are not included in the revised manuscript.

![Formation of HF-like structures in touch domes of the Lgr6/Col1a2 mouse model.\
(**A-D**) Lgr6^creERT2^;Col1a2^creER^;Ptch1^fl/fl^ mice were treated with Tamoxifen (TAM) at 8 weeks of age and dorsal skin was analyzed post TAM as indicated in the figure panels. Time points were chosen when de novo HF buds or HFs were clearly visible in the TDs of Gli1^creERT2^;R26^Tom^;Ptch1^fl/fl^ mice. (**A**) Formation of epithelial buds outside of the touch dome areas at 17 days post TAM treatment, predominantly located in the upper part of the infundibulum connecting to the IFE (blue and green frame) and occasionally in the IFE (yellow frame) (n = 4 mice; biopsies). (**B**) Immunofluorescent co-staining of Keratin 5 (K5) and Syndecan-1 (SDC1) of 17 days post TAM dorsal skin, showing SDC1 positive dermal cells surrounding an epithelial bud from the infundibulum region (red arrowheads). (**C**) 36 days post TAM, a small hair shaft in the IFE/infundibulum area can be observed that was likely newly formed based on its morphology, size and thickness. However, it doesn't seem properly anchored. Inset shows a zoom-in on the indicated area, with added K5 co-staining. (**D**) In 2 touch domes de novo hair follicles or hair shafts were observed based on morphology, size and thickness (white arrowheads) at 31 or 42 days post TAM treatment, respectively (n=3 for 31-35 days post TAM, n=2 for 42-49 days post TAM). BF: bright field. Scale bars: 200um (**A**), 20um (B, C inset), 100um (C panorama), 50um (**D**).](elife-46756-resp-fig1){#respfig1}

2\) The mouse hindpaw (plantar) epidermis is a skin region devoid of hair follicles and sweat glands, ideal to test whether epithelial and stromal Hh-pathway activation can induce de novo HFs from epidermal cells (i.e. outside the touch dome). Thus we probed for *Gli1* expression in the plantar skin using Gli1-LacZ reporter mice. We consistently found small *Gli1*-ΒGAL expressing clusters of epithelial and adjacent stromal cells in the plantar skin (Figure 9B, Figure 9---figure supplement 1A), which we confirmed with short-term lineage tracing in Gli1^creER^/R26^Tom^ mice (TAM at P8w; sample collection 7 days later) (Figure 9C, Figure 9---figure supplement 1B). Testing for de novo HF induction, we analyzed the hindpaws of Gli1^creER^/R26^Tom^/Ptch1^fl/fl^ mice and control littermates (Gli1^creER^/R26^Tom^/Ptch1^fl/wt^) using the same treatment scheme and sample collection times as for dorsal skin (TAM at P8w; sample collection 5 and 9 weeks post TAM). Indeed, we found numerous de novo HFs with hair shafts in the normally hairless region. These HFs were fully Tomato-lineage traced and showed normal inner-layer differentiation based on morphology and K6 staining (Figures 9D-E, Figure 9---figure supplement 2).

Taken together, these experiments in paw skin demonstrate that combined epithelial and stromal Hh-pathway activation can induce de novo HFs from epidermis of hairless skin, i.e. outside of touch dome niches. These experiments are included in the revised manuscript as new Figure 9, Figure 9---figure supplement 1 and 2 and in the subsection "Epithelial and adjacent stromal Hh-pathway activation induces de novo HF formation in hairless paw skin".

> 4\) Do dermal condensates form only in the stroma of TD? If this is the case, the authors may be able to show that the TD area is specialized to form hair follicles.

In Gli1^creER^/R26^Tom^/Ptch1^fl/fl^ mice the stromal cells of both touch dome and HF isthmus can be targeted (see detailed answer below in point 5). Although we observed de novo HFs in every touch dome (i.e. 100%), we also observed at very low frequency in the HF isthmus area early HF buds and de novo HFs. As shown in point 5 below, we have now added representative images and quantification of de novo HFs in the HF isthmus area, which support that de novo HFs can also form outside touch dome areas in dorsal skin.

It is interesting to note that in mice with Hh-pathway activation in the stroma (Col1a2^CreER^/ R26^Tom^/Ptch1^fl/fl^), dermal cell condensations can emerge next to the HF infundibulum as well as under the normal IFE (Figure 6G, Figure 6---figure supplement 2B), which is in support of dermal condensate formation not being restricted to the touch dome areas.

> 5\) In Figure 1D, Gli1 is positive in follicular epithelium and surrounding stromal cells of guard hairs. When Hh is activated in Gli1/Tom/Ptch1^fl/fl^, did de novo hair follicles form in the Gli1+ area of guard hairs? It may help support that TD is a primed structure to form hair follicles in adult unwounded mouse skin.

We have now carefully assessed potential de novo HF formation in the HF isthmus areas of Gli1^creERT2^/R26^Tom^/Ptch1^fl/fl^ and control mice.

In Gli1^creERT2^/R26^Tom^/Ptch1^fl/fl^ mice we observed HFs that were most likely -- based on their morphology and positioning -- formed de novo HFs (Figure 8C). Unfortunately, it was not possible (as it was for de novo HFs in the touch dome) to unequivocally determine de novo HFs through lineage tracing of the infundibulum because these isthmus-associated de novo HFs seem to directly merge into the isthmus area of pre-existing HFs. However, we observed HFs in the isthmus areas with hair shafts that were thinner and often had a bent shape, which is very similar to touch dome derived de novo HFs (e.g. Figure 1I). In addition, dorsal mouse skin that is harvested at postnatal week 17 usually contains HFs with 3 hair shafts (3 rounds of anagen); however, HFs containing one of these thinner hair shafts often had in total four hair shafts (dependent on the tissue cut of 60 micrometer thickness, not all club hairs/hair shafts are present in the same section) which is an additional indication for the presence of a newly formed HF. Importantly, neither HFs with four hair shafts nor HFs with morphological de novo appearance have been observed in phenotypically normal control skin (Gli1^creERT2^/R26^Tom^/Ptch1^fl/wt^) or in skin with HF tumors (Lgr6^creERT2^/R26^Tom^/Ptch1^fl/fl^).

We quantified the frequency of de novo HFs in large skin panoramas from Gli1^creERT2^/R26^Tom^/Ptch1^fl/fl^, Gli1^creERT2^/R26^Tom^/Ptch1^fl/wt^, Lgr6^creERT2^/R26^Tom^/Ptch1^fl/wt^ and Lgr6^creERT2^/R26^Tom^/Ptch1^fl/fl^ mice (Figure 8D) and found that approx. 2% of HFs formed isthmus-associated de novo HFs. de novo HF formation was not associated with one specific hair type (e.g. guard), which is in line with the occurrence of adjacent epithelial and stromal GLI1+ cells also in the isthmus of zig-zag HFs (Figure 8A-B). Reassuringly, and as expected, we did not observe de novo HFs in skin of Lgr6^creERT2^/R26^Tom^/Ptch1^fl/fl^ mice, which lack stromal cells with high Hh signaling in the HF isthmus (*Lgr6* is not expressed in stromal cells of the HF isthmus; Füllgrabe et al., 2015).

Taken together, these results support that cells in the isthmus area (i.e. outside of touch dome niches) are competent to induce de novo HFs when high levels of Hh signaling (via Ptch1^fl/fl^) co-occur in the epithelium and adjacent stroma. These results are now included in the revised manuscript in Figure 8 and in the subsection "Cells outside TD niches can give rise to de novo HFs".

> 6\) Although this work clearly shows that localized Hedgehog signaling can induce hair follicles, the equivalency of these structures to existing follicles and the lack of mechanism should be addressed as detailed below.

Please find our responses to comments 7, 8 and 9 below.

> 7\) The de novo hair follicles form under constant Hedgehog signaling, which is typically only active during the anagen phase of the hair follicle and is shut down to allow the hair follicle to proceed to catagen/telogen. Do the de novo hair follicles cycle when induced with the Gli1-CreERT2 promoter?

The de novo HFs clearly enter catagen/telogen after their first anagen (morphogenesis) as the majority of the de novo HFs in skin 9 weeks post tamoxifen are in telogen. We administered tamoxifen at 8 weeks of age. Ten days post tamoxifen we observe first de novo HF buds, 5 weeks post tamoxifen de novo HFs are in anagen (Figure 1I, Figure 2A), and 9 weeks post tamoxifen almost all de novo HFs are in telogen (Figure 2C and Figure 2---figure supplement 2). These de novo HFs have one hair shaft as this is their first telogen after morphogenesis. In the revised manuscript, we have now added additional text to better clarify this point (subsection "Characterization of de novo hair follicles in touch domes") and added Figure 2---figure supplement 2better depicting de novo HFs in telogen 9 weeks post tamoxifen.

That de novo HFs can enter catagen/telogen despite constitutive Hh-pathway activation is not unexpected. In normal skin (i.e. during physiological hair cycling), Brownell et al. have shown that the regressing catagen follicle continued to broadly express *Gli1* using Gli1^LacZ^ reporter mice (Brownell et al., 2011; Figure 1A). With *Gli1* expression being among the most reliable direct target genes for active Hh signaling, Brownell et al. show that Hh signaling is active during catagen as well as in the telogen HF. Moreover, and most relevant for our study, HFs with continuous Hh-pathway activation via *Ptch1* inactivation can precede into catagen and telogen, which was shown in Lgr5^creERT2^/Ptch1^fl/fl^ mice where HFs entered catagen and proceeded into telogen (Kasper et al., 2011; Figure 4B, C and Supplementary Figure 6). In the follow up experiments, where Lgr5^creERT2^/Ptch1^fl/fl^ mice were tamoxifen treated at P20 and taken 13 weeks later, dorsal skin contained HFs with 3 hair shafts (instead of 1 hair shaft at P20), signifying that HFs underwent several hair growth cycles ([Author response image 2](#respfig2){ref-type="fig"}).

![H&E stained dorsal skin of Lgr5^creERT2^/Ptch1^fl/fl^ mice, treated with tamoxifen at P20.\
Samples were taken at P16w, when HFs normally have produced 3 hair shafts (i.e. morphogenesis and 2 times anagen). Inset shows a magnified area of left panel with black arrows indicating HFs with 3 hair shafts.](elife-46756-resp-fig2){#respfig2}

In sum, despite constitutive Hh-pathway activation via inactivation of *Ptch1,* de novo HFs do proceed from anagen into the telogen phase, which is in line with previously published work on pre-existing HFs.

> 8\) Is Hedgehog pathway activation necessary for de novo hair follicle formation or merely Ptch1 loss?

In unwounded skin, it has been shown that activation of epithelial β-catenin in mouse skin can induce ectopic (de novo) HFs (Gat et al., 1998; Lo Celso et al., 2004). Importantly, this Wnt/β-catenin-pathway induced ectopic HF development is dependent on an active Hh-signaling pathway. Lichtenberger et al. induced ectopic HF formation using K14DNb-cateninER mice. Deletion of a single *Smo* allele in K14DNb-cateninER mice via *Dermo1Cre* (K14DNb-cateninER/Dermo^Cre^/Smo^fl/fl^) significantly reduced ectopic HF formation, and homozygous *Smo* deletion via Pdgfra^CreER^ (K14DNb-cateninER/Pdgfra^CreER^/Smo^fl/fl^) inhibited ectopic HF formation (Lichtenberger et al., 2016).

In wild type mice,de novo HF formation occurs in the center of large wounds (Ito et al., 2007). This wound-induced HF neogenesis (WIHN) is accompanied by activation of Hh/Gli signaling in the epidermal placodes and dermal condensates (Lim et al., 2018). Lim et al. furthermore demonstrated that both epithelial SHH and dermal SMO expression are necessary for WIHN as K14^creER^/Shh^fl/fl^ and Pdgfra^creER^/Smo^fl/fl^ mice, respectively, do not develop WIHN.

In the canonical Hh-pathway signaling cascade, SHH is upstream of PTCH (PTCH is the receptor for SHH) and SMO is downstream of PTCH (SMO is activated upon PTCH inhibition). Thus, the experiments of Lim et al. and Lichtenberger et al. convincingly demonstrate that for de novo HF formation active Hh/Gli-signaling is necessary. I.e. activation of the Hh-pathway via SHH/PTCH, without it's downstream signaling component SMO that mediates Hh-pathway activation via GLI1/2 transcription factors, would not be sufficient for de novo HF formation.

In our manuscript, we have now added RNA-FISH staining for *Gli1*, which is a reliable readout for active Hh-signaling. These stainings demonstrate that de novo HF buds and established HFs within the TD express high levels of *Gli1* mRNA (i.e. have active Hh/Gli-signaling). Moreover, *Gli1* mRNA-FISH combined with antibody staining for Tomato-lineage tracing also shows that Tomato-tracing (cells with *Ptch1* deletion) and *Gli1* expression are highly correlated (Figure 4F-G, Figure 4---figure supplement 1C-D).

Taken together, in the revised manuscript we added *Gli1* mRNA-FISH staining of de novo HFs, as well as wild-type touch domes and wild-type-embryonic HF placodes/hair germs (Figure 4D-G, Figure 4---figure supplement 1). The results are described on in the subsection "De novo HF formation recapitulates embryonic HF development".

> 9\) Can the hair follicles persist without Hedgehog signaling?
>
> Use of Smo inhibitors such as vismodegib can be helpful to answer these questions by administering the drug after tamoxifen injection or after the hair follicle has already formed.

In the light of the reviewers comment, we administered vismodegib after the de novo HFs in touch domes had already formed. I.e. the aim of this experiment was to reveal if established de novo HFs would persist or would diminish as the BCC-tumor area does. It has been shown previously that BCC-like lesions in dorsal skin of Gli1^creER^/Ptch1^fl/fl^ shrink dramatically upon vismodegib treatment within 7 days (Eberl et al., 2018).

We treated Gli1^creER^/R26^Tom^/Ptch1^fl/fl^ mice with tamoxifen at 8 weeks. Five to seven weeks after tamoxifen treatment when de novo HFs are clearly established in the touch domes, we took a dorsal biopsy prior vismodegib treatment (i.e. untreated biopsy), and then treated the mice with vismodegib for seven days for second sample collection (i.e. 7 days Vismodegib sample). Using the optimized treatment scheme from Eberl et al., 2018 we administered 50mg/kg vismodegib i.p. once a day, for seven days (n = 4 mice) (see experimental scheme in Figure 5A).

Reassuringly, in pre-existing HFs we found considerable reduction of tumor growth as well as complete absence of Ki67 staining when comparing the untreated biopsies with 7-day vismodegib treated samples of the same mice. This reduction in tumor size demonstrated that vismodegib treatment worked well (Figure 5B-C). In touch domes, the tumor areas also dramatically diminished, however the de novo HFs persisted (Figure 5D, Figure 5---figure supplement 1). These experiments confirmed that de novo HFs indeed represent hair follicles that are independent of tumor structures as they persist upon vismodegib treatment when the surrounding BCC-growth areas are nearly gone.

Taken together, we added these new experiments to the revised manuscript (Figure 5, Figure 5---figure supplement 1) and updated the manuscript text accordingly (subsection "De novo HFs persist while BCC-like tumors diminish upon vismodegib treatment").
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